Minimal residual disease-directed individualized therapy for hematological malignancies
10.3760/cma.j.cn115356-20221230-00366
- VernacularTitle:从微小残留病角度看恶性血液病的个体化治疗
- Author:
Liwen WANG
1
;
Chunzi YU
;
Yingjun CHANG
Author Information
1. 北京大学人民医院血液科 北京大学血液病研究所 国家血液系统疾病临床医学研究中心 造血干细胞移植治疗血液病北京市重点实验室，北京 100044
- Keywords:
Hematological malignancies;
Leukemia, myeloid, acute;
Minimal residual disease;
Allogneic hematopoietic stem cell transplantation;
Molecular targeted ther
- From:
Journal of Leukemia & Lymphoma
2023;32(1):12-17
- CountryChina
- Language:Chinese
-
Abstract:
Minimal residual disease (MRD) has been used for warning of relapse and guiding the therapy selection for hematological malignancies including acute leukemia. Based on MRD-related content reported at the 64th American Society of Hematology (ASH) Annual Meeting, this article discusses the progress of MRD-directed individualized therapy for hematological malignancies with a primary focus on acute myeloid leukemia.
